BCM
SNNA

Bridgeway Capital Management’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Bridgeway Capital Management’s Portfolio SNNA Stock Details SNNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-53,200
Closed -$123K – 1433
2019
Q1 		$123K Buy
53,200
+38,000
+250% +$103K ﹤0.01% 1266
2018
Q4 		$35K Hold
15,200
– – ﹤0.01% 1346
2018
Q3 		$225K Buy
+15,200
New +$242K ﹤0.01% 1302

Other funds holding SNNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bridgeway Capital Management's SNNA Position: Q2 2019 in Review

Bridgeway Capital Management sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q2 2019, closing a stake of 53,200 shares — an estimated $123K sold.

Bridgeway Capital Management first reported a position in SNNA in Q3 2018 and held it in 3 quarters. The position peaked at $225K in Q3 2018. 48 funds tracked by Wall St. Rank hold SNNA as of Q2 2019.

  • Bridgeway Capital Management reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Bridgeway Capital Management sold 53,200 Sienna Biopharmaceuticals, Inc. shares in Q2 2019, an estimated $123K.
  • Bridgeway Capital Management first reported a position in Sienna Biopharmaceuticals, Inc. in Q3 2018 and held it in 3 quarters.
  • Bridgeway Capital Management's Sienna Biopharmaceuticals, Inc. position peaked at $225K in Q3 2018.
  • 48 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q2 2019.

Based on Bridgeway Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.